Autoimmune - We are Live!

8:15 am Registration & Coffee Networking

9:15 am Chair’s Opening Remarks

  • Fred Aslan President & Chief Executive Officer, Artiva Biotherapeutics, Inc

Sharing Clinical Data: Improving Outcomes for Lupus Patients

9:20 am Developing CD19 CAR-T for Autoimmune Disease & Early Clinical Insights

  • Samik Basu Chief Scientific Officer, Cabaletta Bio


  • Leveraging pre-existing experience with CAR-T in oncology and HSCT in autoimmune disease for CAR-T in autoimmune disease
  • Designing the optimal CD19 CAR-T for autoimmune disease
  • Discussing early clinical insights from SLE patients treated with CD19 CAR-T cells

9:50 am Developing Cutting Edge Life-Saving CAR-T Therapies for Systemic Lupus Erythematosus (SLE) Patients

  • Greg Deener Chief Executive Officer, iCell Gene Therapeutics


  • Developing a compound chimeric antigen receptor (cCAR) targeting both CD19 and BCMA to exert more comprehensive killing and prevent antigen escape
  • Sharing clinical data and long-term outcomes, with the first patient being administered over 4 years ago
  • Demonstrating well tolerated, long-term remission in a single administration

10:20 am Morning Break & Networking

Improving Outcomes for Patients with Autoimmune Indications Beyond Lupus

11:00 am Pioneering RNA Cell Therapy for Autoimmune Diseases


  • Developing the first RNA cell therapy in an autoimmune disease, Descartes-08
  • Sharing long-term follow-up data from the phase 1/2a open-label trial in patients with myasthenia gravis
  • Discussing the next steps for Descartes-08 in myasthenia gravis and other autoimmune indications

11:30 am Treating Autoimmunity with Tregs


  • Developing Treg cell therapies for autoimmune diseases
  • Sharing results and lessons from completed clinical trials with Tregs in type 1 diabetes and multiple sclerosis
  • Outlining future challenges in the application of Tregs as medicinal products

12:00 pm Lunch Break & Networking

Planning for the Clinic & Optimizing Clinical Trial Design

1:00 pm Developing a CAR-T for Autoimmune Disease Clinical Program Effectively

  • David Porter Director, Cell Therapy and Transplant, University of Pennsylvania


  • Discussing background and outcomes using CAR-T cells in hematological malignancies
  • Developing a multidisciplinary program to administer CAR-T cell therapies for noncancer indications
  • Identifying challenges when using CAR-T cells in autoimmune diseases rather than in B-cell malignancies

1:30 pm Treg Cell Therapy in Autoimmunity: Perspective on Target Patient Populations & Clinical Strategy

  • Tatiana Ort Head of Bioscience, Immunology, AstraZeneca


  • Developing "armed" Tregs as a promising therapeutic option to induce immune tolerance
  • Understanding considerations for diseases and target patient populations
  • Giving an overview of the clinical development strategy 

2:00 pm Panel Discussion: Improving Clinical Endpoints & Optimizing Trial Design

  • Peter Merkel Chief, Division of Rheumatology & Professor, Medicine & Epidemiology, University of Pennsylvania
  • Tamas Shisha Executive Director, Head of Rheumatology Translational Medicine, Novartis Institutes for BioMedical Research
  • David Close Executive Director, Early Clinical Development Immunology, AstraZeneca


  • Moving from oncology to autoimmunity, do we need to adapt clinical trial design? Are basket trials the way forward?
  • How do we improve communication between hematology, rheumatology, and oncology disciplines?
  • What should clinical readouts and endpoints look like for autoimmune disease? How can we implement surrogate endpoints?

2:45 pm Afternoon Break & Networking

Looking to the Future: Beyond T Cells & the Road Towards Commercialization

3:15 pm ADCC Enhancement of Monoclonal Antibodies in Autoimmune Disease with AlloNK®

  • Heather Raymon Senior Vice President, Research & Early Development, Artiva Biotherapeutics


  • Developing a non-engineered, allogeneic NK cell product for autoimmune disease
  • Combining with monoclonal antibodies to enhance ADCC against pathogenic B-cells
  • Discussing lessons from NHL and application to lupus nephritis

3:45 pm Panel Discussion: Making Cell Therapy for Autoimmune Diseases a Commercial Reality

  • Adel Nada Co-Founder & Chief Executive Officer, GentiBio
  • Greg Deener Chief Executive Officer, iCell Gene Therapeutics
  • James Li Co-Founder, Chairman & Chief Executive Officer, JW Therapeutics


  • What challenges do we expect to encounter on our way towards commercial approval (i.e., regulatory, manufacturing, pricing)?
  • With autoimmune diseases having larger patient population than oncology indications, how will we deal with the demand?
  • How do we overcome these challenges to ensure we get better cell therapies for patients in need, faster?

4:30 pm Chair’s Closing Remarks

  • Fred Aslan President & Chief Executive Officer, Artiva Biotherapeutics, Inc

4:40 pm End of Conference